July 14, 2012

BRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

Key Points

Key points are not available for this paper at this time.

Abstract

This study shows that cells harboring BRAF(L597R) mutants are sensitive to MEK inhibitor treatment, providing a rationale for routine screening and therapy of BRAF(L597R)-mutant melanoma.

Perguntar à IA

Bookmark

Cite This Study

Dahlman et al. (Sat,) studied this question.

synapsesocial.com/papers/69d89ba3183921ebcaae2d49 https://doi.org/https://doi.org/10.1158/2159-8290.cd-12-0097

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1High-throughput oncogene mutation profiling in human cancer2007 · 996 citations
2Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group2012 · 1,342 citations
3Accurate whole human genome sequencing using reversible terminator chemistry2008 · 3,770 citations
4Predictors of Competing Mortality in Advanced Head and Neck Cancer2009 · 434 citations
5Cancer statistics, 20112011 · 4,080 citations

Perguntar à IA

Bookmark